Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis has signed a research collaboration with Karolinska Institutet to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.
Subscribe to our email newsletter
Karolinska Institutet will use Advaxis immunotherapies to develop allergy treatments using the models that were developed at Karolinska.
Advaxis chairman/CEO Thomas Moore said: "The Karolinska Institutet is a world-renowned group of researchers and we are pleased that our immunotherapies may help to better understand allergic responses and potentially provide additional prevention and treatment options."